Citation Impact
Citing Papers
Combination formoterol and budesonide as maintenance and reliever therapy versus current best practice (including inhaled steroid maintenance), for chronic asthma in adults and children
2013
Clinical Practice Guidelines for the Diagnosis and Management of Intravascular Catheter-Related Infection: 2009 Update by the Infectious Diseases Society of America
2009 Standout
Omalizumab for asthma in adults and children
2014
Budesonide/formoterol and formoterol provide similar rapid relief in patients with acute asthma showing refractoriness to salbutamol
2006
Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease
2007 Standout
Perception of airway narrowing in a general population sample
1997
The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation
2005
Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose
2008 Standout
Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial
2003
Montelukast added to budesonide in children with persistent asthma: A randomized, double-blind, crossover study
2001
Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE
2004
Cross-cultural adaptation of health-related quality of life measures: Literature review and proposed guidelines
1993 Standout
Comparative effectiveness of long term drug treatment strategies to prevent asthma exacerbations: network meta-analysis
2014
Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial
2002
Rationale and Clinical Results of Inhibiting Interleukin-5 for the Treatment of Severe Asthma
2013
Diagnostic Value of the Bronchial Provocation Test With Methacholine in Asthma
1993
Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial
2017
Quality of life bibliography and indexes: 1993 update
1995
Pulmonary fibrosis: pathogenesis, etiology and regulation
2009 Standout
Results of a Home-Based Environmental Intervention among Urban Children with Asthma
2004 Standout
Onset and duration of protection against exercise-induced bronchoconstriction by a single oral dose of montelukast
2006
Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients
1999
Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma
2014 Standout
Effect of eicosapentaenoic acid in asthma
1988
Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma
2009 Standout
Update on optimal use of omalizumab in management of asthma
2011
IgE and mast cells in allergic disease
2012 Standout
Efficacy and safety of a CXCR2 antagonist, AZD5069, in patients with uncontrolled persistent asthma: a randomised, double-blind, placebo-controlled trial
2016
Bronchial hyperresponsiveness and its relationship to asthma in childhood
1993
Occupational asthma
1997
Assessment of Quality-of-Life Outcomes
1996 Standout
Fibrosis of the Lung and Other Tissues: New Concepts in Pathogenesis and Treatment
2001
Effect of cysteinyl-leukotriene receptor antagonist ICI 204.219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects
1991
The Poorly Explored Impact of Uncontrolled Asthma
2013
Nonresolving Inflammation
2010 Standout
Dietary Fish Oil Effects on Seasonal Hay Fever and Asthma in Pollen-sensitive Subjects
1993
Asthma: defining of the persistent adult phenotypes
2006
Airway remodeling-associated mediators in moderate to severe asthma: Effect of steroids on TGF-β, IL-11, IL-17, and type I and type III collagen expression
2003
Asthma
2017 Standout
Effects of an Anti-TSLP Antibody on Allergen-Induced Asthmatic Responses
2014
Anti-interleukin-5 therapy in severe asthma
2013
Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial
2003
Molecular pathology of allergic disease
2000
Pharmacological treatment of severe, therapy-resistant asthma in children: what can we learn from where?
2011
A Study to Evaluate Safety and Efficacy of Mepolizumab in Patients with Moderate Persistent Asthma
2007
Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials
2016
Long-acting ?2-agonists in management of childhood asthma: A critical review of the literature
2000
Allergic Rhinitis and Its Impact on Asthma
2001 Standout
Fibrotic disease and the TH1/TH2 paradigm
2004 Standout
n−3 Polyunsaturated fatty acids, inflammation, and inflammatory diseases
2006 Standout
Effect of montelukast added to inhaled budesonide on control of mild to moderate asthma
2003
The development of allergic inflammation
2008 StandoutNature
Add‐on omalizumab improves day‐to‐day symptoms in inadequately controlled severe persistent allergic asthma
2008
Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option?
2005
Evidence for phenotype-driven treatment in asthmatic patients
2011
Asthma
2001 Standout
Airway remodeling in asthma
1999
Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study
2006
Relation between Airway Responsiveness and Serum IgE in Children with Asthma and in Apparently Normal Children
1991
Pharmacokinetics and systemic activity of fluticasone via Diskus® and pMDI, and of budesonide via Turbuhaler®
2001
Clinician’s Guide to Cardiopulmonary Exercise Testing in Adults
2010 Standout
Severe asthma treatment: need for characterising patients
2005
Asthma and Wheezing in the First Six Years of Life
1995 Standout
D prostanoid receptor 2 (chemoattractant receptor–homologous molecule expressed on TH2 cells) protein expression in asthmatic patients and its effects on bronchial epithelial cells
2014
Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma
2014 Standout
The relationship between airway inflammation and bronchial hyperresponsiveness
1989
Asthma phenotypes: the evolution from clinical to molecular approaches
2012 Standout
Alternative Activation of Macrophages: Mechanism and Functions
2010 Standout
Addition of leukotriene antagonists to therapy in chronic persistent asthma: a randomised double-blind placebo-controlled trial
2001
Global strategy for asthma management and prevention: GINA executive summary
2007 Standout
Recent developments in asthma management
2005
Remodeling in Asthma
2009
Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial
2012 Standout
Airway Mucus Function and Dysfunction
2010 Standout
Exposure to House-Dust Mite Allergen (Der pI) and the Development of Asthma in Childhood
1990 Standout
Asthma exacerbations {middle dot} 4: Prevention
2006
Influence of comorbid conditions on asthma
2009
A randomized trial of benralizumab, an antiinterleukin 5 receptor α monoclonal antibody, after acute asthma
2014
Role of interleukin 10 in specific immunotherapy.
1998 Standout
Eosinophil protein in airway macrophages: A novel biomarker of eosinophilic inflammation in patients with asthma
2010
The effect of immunotherapy on bronchial hyperresponsiveness and eosinophil cationic protein in pollen-allergic patients
1988
Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years
1999 Standout
Pharmacological strategies for self-management of asthma exacerbations: Table 1—
2006
Asthma exacerbations in children immediately following stressful life events: a Cox's hierarchical regression
2004
Management of asthma in pregnancy guided by measurement of fraction of exhaled nitric oxide: a double-blind, randomised controlled trial
2011
If it goes up, must it come down? Chronic stress and the hypothalamic-pituitary-adrenocortical axis in humans.
2007 Standout
Mechanisms of occupational asthma
2009
The increasing challenge of discovering asthma drugs
2011
Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsìveness, and the late asthmatic response
2000 Standout
Sensitivity and maximal response to methacholine in perennial and seasonal allergic rhinitis
1996
Late-phase IgE-mediated reactions
1988
Effect of inhaled budesonide on seasonal changes in sensitivity and maximal response to methacholine in pollen-sensitive asthmatic subjects
1994
Repeated Methacholine Challenge Produces Tolerance in Normal but Not in Asthmatic Subjects
1992
Anti‐immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti‐inflammatory activity and clinical efficacy
2005
Developmental Pharmacology — Drug Disposition, Action, and Therapy in Infants and Children
2003 Standout
Asthma
2000 Standout
Symptom Perception during Acute Bronchoconstriction
2000
Airway Inflammation in Mild Intermittent and in Persistent Asthma
1998
Two Subphenotypes of Childhood Asthma That Differ in Maternal and Paternal Influences on Asthma Risk
1999
Zafirlukast Improves Asthma Control in Patients Receiving High-Dose Inhaled Corticosteroids
2000
Guidelines for Methacholine and Exercise Challenge Testing—1999
2000 Standout
Asymptomatic Airway Hyperresponsiveness: A Three-year Follow-up
1997
Occupational Asthma
2005
Differences in Airway Inflammation in Patients with Fixed Airflow Obstruction Due to Asthma or Chronic Obstructive Pulmonary Disease
2003
Airway Subepithelial Fibrosis in a Murine Model of Atopic Asthma
2000
Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease
2012 Standout
Clinical, Radiologic, and Induced Sputum Features of Chronic Obstructive Pulmonary Disease in Nonsmokers
2002
Airway Narrowing in Healthy Humans Inhaling Methacholine without Deep Inspirations Demonstrated by HRCT
2000
Inflammatory Cell Distribution within and along Asthmatic Airways
1998
Interleukin-13 Induces Tissue Fibrosis by Selectively Stimulating and Activating Transforming Growth Factor β1
2001 Standout
Physiological Implications of Hydrogen Sulfide: A Whiff Exploration That Blossomed
2012 Standout
Effect of house dust mite avoidance measures on adult atopic asthma.
1988
Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma
2003
Omalizumab in Severe Allergic Asthma Inadequately Controlled With Standard Therapy
2011
Prevalence of atopy and range of bronchial response to methacholine in 7 and 11 year old schoolchildren.
1989
Chromone: A Valid Scaffold in Medicinal Chemistry
2014 Standout
British Guideline on the Management of Asthma
2008
The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations
2015 Standout
The Asthma Epidemic
2006 Standout
Prostaglandins and Leukotrienes: Advances in Eicosanoid Biology
2001 StandoutScience
Decreased pulmonary vascular permeability in aquaporin-1-null humans
2002 StandoutNobel
Alcohol Dehydrogenase Restricts the Ability of the Pathogen Candida albicans To Form a Biofilm on Catheter Surfaces through an Ethanol-Based Mechanism
2006
Design, Synthesis, and Inhibitory Activity of Potent, Photoswitchable Mast Cell Activation Inhibitors
2013 StandoutNobel
The Effects of Plant Flavonoids on Mammalian Cells:Implications for Inflammation, Heart Disease, and Cancer
2000 Standout
Interleukin-13: Central Mediator of Allergic Asthma
1998 StandoutScience
Intercellular Adhesion Molecule-1 (ICAM-1) in the Pathogenesis of asthma
1990 Science
Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children
2012
Interleukin-5, eosinophils, and disease
1992 Standout
Bronchoprovocation Methods: Direct Challenges
2003
Works of LP Boulet being referenced
Single-dose desloratadine and montelukast and allergen-induced late airway responses
2009
Airway inflammation in nonasthmatic subjects with chronic cough.
1994
Is reactive airways dysfunction syndrome a variant of occupational asthma?
1994
Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma
2004
Airway remodelling: the future: Table 1—
2007
Quality of life of subjects with occupational asthma
1993
Comparative assessment of safety and efficacy of inhaled corticosteroids: report of a committee of the Canadian Thoracic Society
1998
Airway responsiveness and bronchial-wall thickness in asthma with or without fixed airflow obstruction.
1995
Efficacy and tolerability of anti‐immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR
2004
Airway inflammation after removal from the causal agent in occupational asthma due to high and low molecular weight agents
1994
Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations
2006
Budesonide/formoterol maintenance and reliever therapy: impact on airway inflammation in asthma
2008
Influence of smoking on airway inflammation and remodelling in asthma
2008
Comparative efficacy of once-daily ciclesonide and budesonide in the treatment of persistent asthma
2006
The CONCEPT trial: A 1-year, multicenter, randomized,double-blind, double-dummy comparison of a stable dosing regimen of salmeterol/fluticasone propionate with an adjustable maintenance dosing regimen of formoterol/budesonide in adults with persistent asthma
2005
Tolerance to the protective effects of salmeterol on methacholine-induced bronchoconstriction: influence of inhaled corticosteroids
1998
Comparative degree and type of sensitization to common indoor and outdoor allergens in subjects with allergic rhinitis and/or asthma
1997
Lower airways remodeling in nonasthmatic subjects with allergic rhinitis.
1996
Increased maximal airway response to methacholine during seasonal allergic rhinitis in nonasthmatic subjects: relationships with airway wall thickness and inflammation
1995
Montelukast reduces airway eosinophilic inflammation in asthma: a randomized, controlled trial
1999
Omalizumab, an anti-IgE antibody, improves both asthma- and rhinitis-related quality of life in patients with concomitant moderate-severe disease
2004
Asthma and increases in nonallergic bronchial responsiveness from seasonal pollen exposure
1983
Perception of breathlessness during bronchoconstriction induced by antigen, exercise, and histamine challenges.
1990
Bronchial responsiveness increases after seasonal antigen exposure in non-asthmatic subjects with pollen-induced rhinitis.
1989